RESEARCH · TESAMORELIN · VAT / NAFLD
Tesamorelin, Visceral Fat and the Liver: What the VAT and NAFLD Trial Series Shows
Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue. Our earlier article, Tesamorelin: the GHRH analogue, the GH/IGF-1 axis and published clinical studies, covers mechanism and the broad clinical record. This article focuses on the imaging and liver series: how visceral adipose tissue (VAT) changed in the large HIV lipodystrophy trials, and what later NAFLD studies reported for hepatic fat and related biology. PurixLab’s Tesamorelin 5mg is a research material for laboratory research use only; the trials below describe a regulated clinical drug product under protocol conditions.
VAT selectivity in the phase 3 programme
In a 26-week randomised trial of 412 people with HIV and excess abdominal fat, CT-measured VAT fell 15.2% with tesamorelin and rose 5.0% with placebo. Triglycerides fell 50 mg/dL versus a 9 mg/dL rise on placebo, and the total-to-HDL cholesterol ratio moved favourably (−0.31 versus +0.21). IGF-I rose 81.0% on tesamorelin and fell 5.0% on placebo. Glycaemic measures did not differ significantly between groups [1].
A pooled analysis of two phase 3 studies (806 participants randomised 2:1) reported a VAT treatment effect of −15.4% at week 26 (−24 ± 41 versus +2 ± 35 cm²), with essentially no change in abdominal subcutaneous adipose tissue (treatment effect −0.6%). Triglycerides and the cholesterol-to-HDL ratio improved; mean IGF-I rose 108 ± 112 versus −7 ± 64 ng/mL on placebo. In participants kept on tesamorelin to week 52, VAT reduction was maintained (−17.5 ± 23.3%) without clinically meaningful glucose differences at weeks 26 and 52 in that pooled dataset [2].
A post hoc imaging analysis among VAT responders (≥8% VAT reduction) found that CT fat density rose in both visceral and subcutaneous compartments with tesamorelin relative to placebo over 26 weeks, an effect that persisted after adjustment for fat area — a reminder that quantity and density can move together [3].
From visceral fat to liver fat
VAT and NAFLD travel together clinically, so Stanley and colleagues tested whether VAT-targeted GHRH agonism would change hepatic fat. In a 50-participant, 6-month randomised trial in antiretroviral-treated people with HIV and abdominal fat accumulation, the VAT treatment effect was −42 cm² (95% CI −71 to −14). Liver fat (lipid-to-water percentage by spectroscopy) showed a net treatment effect of −2.9 percentage points. Fasting glucose rose transiently at 2 weeks but changes at 6 months were not significant [4].
The larger multicentre NAFLD trial enrolled 61 people with HIV and hepatic fat fraction (HFF) ≥5%. Over 12 months, tesamorelin produced a greater HFF reduction than placebo (absolute effect size −4.1%, 95% CI −7.6 to −0.7; relative reduction from baseline −37%). After 12 months, 35% of people on tesamorelin and 4% on placebo had HFF below 5%. Changes in fasting glucose and glycated haemoglobin did not differ between groups at 12 months [5].
Fibrosis context and hepatic gene programmes
In the NAFLD trial population, baseline biopsies showed hepatic fibrosis in 43% of participants. Among placebo-treated participants with paired biopsies, 38% had fibrosis progression over 12 months, and higher baseline VAT predicted progression (odds ratio 1.37 per 25 cm² higher VAT) [6]. Transcriptomic analysis of paired biopsies found that tesamorelin increased hallmark oxidative-phosphorylation gene sets and decreased sets linked to inflammation, tissue repair and cell division, with fibrosis-related gene scores improving in parallel among treated participants [7]. An earlier pooled analysis had already linked clinically meaningful VAT reduction to improved ALT and AST among participants with elevated baseline transaminases [8].
What remains open
- Population. The VAT and NAFLD series is almost entirely in people with HIV on antiretroviral therapy; generalisation to other NAFLD populations is not established by these trials [5,2].
- Weight versus direct hepatic effect. VAT reduction, IGF-I rises and liver-fat falls co-occur; the studies do not fully isolate a liver-autonomous mechanism [4,5].
- Long-term histology. Authors of the 12-month NAFLD trial called for further work on long-term histologic outcomes [5].
- Research versus clinical product. Trial materials, potency and quality systems are not the same as a research vial; nothing above is a claim about PurixLab stock.
Tesamorelin 5mg at PurixLab
Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338 · doi:10.1056/NEJMoa072375
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713 · doi:10.1210/jc.2010-0490
- Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. PubMed 33756511 · PMC8243807 · doi:10.1097/QAD.0000000000002897
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. PubMed 25038357 · PMC4363137 · doi:10.1001/jama.2014.8334
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PubMed 31611038 · PMC6981288 · doi:10.1016/S2352-3018(19)30338-8
- Fourman LT, Stanley TL, Zheng I, et al. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021;72(12):2087-2094. PubMed 32270862 · PMC8204775 · doi:10.1093/cid/ciaa382
- Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):140134. PubMed 32701508 · PMC7455119 · doi:10.1172/jci.insight.140134
- Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253-2259. PubMed 28832410 · PMC5633509 · doi:10.1097/QAD.0000000000001614